MedTech & Diagnostics
Stryker Executive Compensation (FY25)
SYK · Portage, MI · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 8, 2026
208 figures on this page: 198 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Kevin Lobo, Chair, Chief Executive Officer and President, received $21,401,495 in total compensation for fiscal 2025, and Lobo's total was 2.6% lower than the $21,979,369 reported for fiscal 2024. The company reported a chief executive pay ratio of 403.8:1 for fiscal 2025, against median employee compensation of $53,000. The say-on-pay proposal drew 93.5% of votes cast for or against in favor at the meeting held May 6, 2026 for fiscal 2025. Companies named in the disclosed peer group include Abbott Laboratories, Amgen Inc., Baxter International Inc., Becton, Dickinson and Company and Biogen Inc., among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kevin Lobo: $21,979,369 → $21,401,495 (2.6% lower)
Say-on-pay support: 92.2% → 93.5% (1.3 points higher)
CEO pay ratio: 263:1 → 403.8:1 (53.5% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Stryker's chief executive and what were they paid?
Kevin Lobo, Chair, Chief Executive Officer and President, received $21,401,495 in total compensation for fiscal 2025. Lobo's total was 2.6% lower than the $21,979,369 reported for fiscal 2024.
What was Stryker's say-on-pay result?
The say-on-pay proposal drew 93.5% of votes cast for or against in favor at the meeting held May 6, 2026 for fiscal 2025.
Which companies are in Stryker's peer group?
Companies named in the disclosed peer group include Abbott Laboratories, Amgen Inc., Baxter International Inc., Becton, Dickinson and Company and Biogen Inc., among others.
What is Stryker's chief executive pay ratio?
The company reported a chief executive pay ratio of 403.8:1 for fiscal 2025, against median employee compensation of $53,000.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin Lobo Chair, Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Glenn Boehnlein Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Viju Menon Group President, Global Quality and Operations | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin Lobo Chair, Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Glenn Boehnlein Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Spencer Stiles Group President, Orthopaedics and Spine | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Viju Menon Group President, Global Quality and Operations | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin Lobo Chair, Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Glenn Boehnlein Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Spencer Stiles Group President, Orthopaedics and Spine | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Viju Menon Group President, Global Quality and Operations | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin Lobo Chair, Chief Executive Officer and President | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Spencer Stiles Group President, Orthopaedics | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
J. Andrew Pierce Group President, MedSurg and Neurotechnology | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Preston Wells Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Viju Menon Group President, Global Quality and Operations | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Glenn Boehnlein Advisor to the Chief Executive Officer and Former Vice President, Chief Financial Officer Departed during or after this year | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| J. Andrew Pierce | Options/SARs | ◇ | — | — | — withheld | — | — | ◇ |
| J. Andrew Pierce | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Kevin Lobo | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Kevin Lobo | Options/SARs | ◇ | — | — | — withheld | — | — | ◇ |
| Preston Wells | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Preston Wells | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Preston Wells | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Spencer Stiles | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Spencer Stiles | Options/SARs | ◇ | — | — | — withheld | — | — | ◇ |
| Viju Menon | Options/SARs | ◇ | — | — | — withheld | — | — | ◇ |
| Viju Menon | PSU | ◇ | — | ◇ | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Sherilyn S. McCoy Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Andrew K. Silvernail | ◇ | ◇ | — | — | — | — | ◇ |
Mary K. Brainerd | ◇ | ◇ | — | — | — | — | ◇ |
Giovanni Caforio, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Rachel M. Ruggeri | ◇ | ◇ | — | — | — | — | ◇ |
Lisa M. Skeete Tatum | ◇ | ◇ | — | — | — | — | ◇ |
Ronda E. Stryker | ◇ | ◇ | — | — | — | — | ◇ |
Rajeev Suri | ◇ | ◇ | — | — | — | — | ◇ |
Emmanuel P. Maceda | ◇ | ◇ | — | — | — | — | ◇ |
Allan C. Golston | ◇ | — | — | — | — | — | ◇ |
Kevin A. Lobo served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Abbott Laboratories ABT
- Amgen Inc. AMGN
- Baxter International Inc. BAX
- Becton, Dickinson and Company BDX
- Biogen Inc. BIIB
- Boston Scientific Corporation BSX
- Danaher Corporation DHR
- Eli Lilly and Company LLY
- GE HealthCare Technologies Inc. GEHC
- Gilead Sciences, Inc. GILD
- Labcorp Holdings Inc. LH
- Medtronic plc MDT
- Quest Diagnostics Incorporated DGX
- Regeneron Pharmaceuticals, Inc. REGN
- Thermo Fisher Scientific Inc. TMO
- Viatris Inc. VTRS
- Zimmer Biomet Holdings, Inc. ZBH
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 6, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 8, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 9, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 10, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 4, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 5, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 5, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 1, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 2, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 3, 2017 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Stryker disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Stryker sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
208 figures on this page: 198 cited to the filing that reported them, 10 calculated from figures it prints.
198 cited to the filing
10 calculated from the filing
Documents cited
- 0000310764-26-000029Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-26-0000132025 Grants of Plan-Based Awards · Compensation of Directors · Summary Compensation Table · The 2025 compensation for our non-employee directors was as follows
- 0000310764-25-000085Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-25-000051Summary Compensation Table
- 0000310764-24-000081Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-24-000054Summary Compensation Table
- 0000310764-23-000089Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-23-000051Summary Compensation Table
- 0000310764-22-000081Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-21-000098Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-20-000104Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-19-000091Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-18-000150Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000310764-17-000113Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Stryker executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/SYK (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Stryker and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Stryker discloses
The companies named in SYK's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}